International Journal of Clinical Research
International Journal of Clinical Research. 2024; 8: (12) ; 10.12208/j.ijcr.20240517 .
总浏览量: 106
高州市人民医院 广东茂名
*通讯作者： 吴韦龙,单位：高州市人民医院 广东茂名；
多发性骨髓瘤（Multiple myeloma，MM）是一种源自骨髓浆细胞的恶性肿瘤，其特征为浆细胞异常增殖并伴随单克隆免疫球蛋白的生成。目前，多发性骨髓瘤的治疗主要包括化疗、免疫治疗及干细胞移植等多种手段。白介素-2（Interleukin-2，IL-2）作为一种重要的免疫调节剂，在多种恶性肿瘤的治疗中展现出潜在的应用价值。在MM患者治疗中，IL-2通过增强T细胞、自然杀伤细胞等免疫细胞的活性，有效抑制肿瘤细胞的生长和扩散，从而改善MM患者的预后。本文通过回顾分析2例多发性骨髓瘤患者的临床资料，探讨白介素-2辅助治疗对多发性骨髓瘤患者的影响，以期为多发性骨髓瘤的治疗提供新的思路和方法。
Multiple myeloma (MM) is a malignant tumor originating from bone marrow plasma cells, characterized by abnormal proliferation of plasma cells accompanied by the production of monoclonal immunoglobulins. At present, the treatment of multiple myeloma mainly includes chemotherapy, immunotherapy, stem cell transplantation and other methods. Interleukin-2 (IL-2), as an important immunomodulator, has shown potential application value in the treatment of various malignant tumors. In the treatment of MM patients, IL-2 effectively inhibits the growth and spread of tumor cells by enhancing the activity of immune cells such as T cells and natural killer cells, thereby improving the prognosis of MM patients. This article retrospectively analyzed the clinical data of 2 patients with multiple myeloma to explore the effect of interleukin-2 adjuvant therapy on patients with multiple myeloma, in order to provide new ideas and methods for the treatment of multiple myeloma.
[1] 努尔阿米娜·依明尼亚孜,努尔比亚·阿布都热西提,阿依姆妮萨·阿卜杜热合曼. 来那度胺联合硼替佐米治疗多发性骨髓瘤的临床效果及对免疫功能、不良反应的影响[J]. 临床合理用药,2023,16(31):17-19,24.
[2] 李萍,刘艳贞,李乾,等.注射用重组人白介素-2联合替考拉宁对肺癌伴肺部感染的疗效[J].河南医学研究,2021, 30(22): 4152-4154.
[3] 沙莎,杨秋敏.注射用重组人白介素-2联合化学治疗对三阴性乳腺癌临床疗效及安全性研究[J].药品评价,2023, 20(05): 641-644.
[4] 米瑞华,陈琳,周亚兰,等.干扰素α-1b、白介素-2联合沙利度胺方案治疗急性髓系白血病免疫调节作用的协同机制研究[J].中国实验血液学杂志,2021,29(01):26-31.
[5] 王英.白介素-2联合化疗治疗多发性骨髓瘤的疗效观察[J].当代医学,2021,27(34):24-26.
[6] 郭大凯,高宇,彭玉.白介素-2和干扰素α2b巩固治疗肾透明细胞癌术后患者安全性分析[J].泌尿外科杂志(电子版),2022,14(01):101-103+107.
[7] 邹媚,李燕,周自华.香菇多糖联合白介素-2序贯洛铂胸腔灌注治疗非小细胞肺癌合并恶性胸腔积液的疗效观察[J].中国处方药,2021,19(09):121-123.
[8] 孙桢,李小东,李伟,等.贝伐珠单抗联合白介素-2腹腔灌注治疗恶性腹腔积液的有效性及安全性[J].实用医院临床杂志,2021,18(04):170-173.
[9] 李书芹,杨志勇,吴忆帆,等.多发性骨髓瘤患者血清细胞因子和T细胞免疫功能水平与Mayo分层及预后的相关性[J].中南医学科学杂志,2024,52(05):808-810+842.